#ESMO26 highlights the evolving landscape of lung cancer research. Which phase III findings could shape the next wave of therapeutic advances in #NSCLC and #SCLC?
🧪MedChemExpress #LungCancer research tools: https://www.medchemexpress.com/disease-areas/lung-cancer.html
45 views · 1 like · 1 repost · 0 replies
Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.orgFirst-line BAT8008 (TROP2-ADC) plus BAT1308 (anti-PD-1) for advanced NSCLC: Results from a multicenter phase 2 study
https://esmocongress.esmo.orgCharacterizing resistance mechanisms and predictors of early progression and long-term response to lorlatinib: Circulating tumor DNA (ctDNA) analyses from the CROWN study
https://esmocongress.esmo.orgOverall survival (OS) analysis of telisotuzumab adizutecan in patients (pts) with nonsquamous non-small cell lung cancer (NSQ NSCLC): Phase 1 first-in-human study
https://esmocongress.esmo.orgPhase 2 trial of the PD-1/VEGF bispecific antibody, PF-08634404 (SSGJ-707), plus chemotherapy (chemo) in advanced NSCLC: Updated results
https://esmocongress.esmo.orgFirst-line (1L) olomorasib + pembrolizumab in KRAS G12C-mutant NSCLC: Updated results from LOXO-RAS-20001 and SUNRAY-01
https://esmocongress.esmo.org🔬ESMO 2026 Lung Cancer Abstract Highlights | How are emerging therapies reshaping the lung cancer treatment landscape? These 10 selected phase III studies explore new strategies across #SCLC and #NSCLC, including immunotherapy, next-generation #ADCs and targeted approaches to treatment resistance. 🔹DeLLphi-305 (LBA3): Tarlatamab + durvalumab vs. durvalumab alone as first-line maintenance for ES-SCLC, testing DLL3-directed T-cell engagement earlier in treatment. 🔹OptiTROP-Lung06 (LBA66): Sacituzumab tirumotecan (TROP2 ADC) + pembrolizumab vs. chemotherapy + pembrolizumab in first-line PD-L1-negative advanced nonsquamous NSCLC. 🔹OptiTROP-Lung04 (LBA67): Final overall survival analysis of sacituzumab tirumotecan vs. platinum-based chemotherapy after EGFR-TKI progression in EGFR-mutated NSCLC. 🔹Sigvotatug Vedotin (LBA68): A phase III comparison with docetaxel in previously treated nonsquamous NSCLC, examining efficacy and safety. 🔹KRASCENDO 1 (LBA5): Divarasib vs. sotorasib or adagrasib in previously treated KRAS G12C-mutated NSCLC, offering a direct comparison within the targeted therapy class. 🔹SAFFRON (LBA6): Osimertinib + savolitinib vs. platinum-pemetrexed after osimertinib progression in EGFR-mutated NSCLC with MET overexpression and/or amplification. 🔹SANOVO (LBA69): Savolitinib + osimertinib vs. osimertinib alone in treatment-naïve EGFR-mutated NSCLC with MET overexpression, exploring upfront dual-target inhibition. 🔹PANKU-Lung01 (LBA71): Izalontamab brengitecan, a bispecific ADC, in EGFR-mutated nonsquamous NSCLC after progression on a third-generation EGFR-TKI. 🔹HERON-Lung01 (LBA72): Ruzaltatug rezetecan, a HER3-directed ADC, vs. platinum-based chemotherapy after EGFR-TKI progression in EGFR-mutated advanced NSCLC. 🔹Neotorch (LBA64): Final analysis of perioperative toripalimab + chemotherapy in resectable stage II-III NSCLC, focusing on long-term outcomes. 🔗Read more: https://oncodaily.com/oncolibrary/lung-oncology/esmo-2026-lung 💡MedChemExpress offers 3900+ tools for lung cancer research: https://www.medchemexpress.com/disease-areas/lung-cancer.html #ESMO26 #ESMO2026 #ESMO #LungCancer #CancerResearch #Oncology在 X 查看被引用的帖子
Source: MedChemExpress-US · x.com